Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic spontaneous urticaria
Pharma
After FDA says no on Dupixent for hives disorder, Japan says yes
Four months after the FDA rejected Sanofi and Regeneron’s Dupixent to treat CSU, Japan has signed off on the treatment in the indication.
Kevin Dunleavy
Feb 16, 2024 10:54am
FDA rejects Sanofi, Regeneron's Dupixent to treat hives disorder
Oct 23, 2023 10:38am
Novartis targets new fields—and CAR-T—for immunology growth
May 10, 2023 5:00pm
Sanofi's Dupixent comes up short, stops hives trial
Feb 18, 2022 10:35am
Sanofi, Regeneron aim Dupixent toward 5 new approvals—and $11B
Jun 11, 2020 10:20am
Novartis, aiming to keep Xolair sales, pushes successor to ph3
Dec 6, 2018 11:20am